Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
23.49
+0.09 (+0.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
604,376
Open
23.31
Bid (Size)
22.85 (3)
Ask (Size)
24.31 (8)
Prev. Close
23.40
Today's Range
23.28 - 23.52
52wk Range
23.24 - 35.88
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 23, 2024
Via
Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
September 17, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.
Via
Chartmill
Performance
YTD
-26.85%
-26.85%
1 Month
-14.30%
-14.30%
3 Month
-8.03%
-8.03%
6 Month
-20.78%
-20.78%
1 Year
-31.99%
-31.99%
More News
Read More
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
September 16, 2024
Via
Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Expert Ratings For Genmab
September 09, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
September 03, 2024
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
August 26, 2024
Via
Chartmill
Decoding 10 Analyst Evaluations For Genmab
August 20, 2024
Via
Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
Business Wire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From
Genmab A/S
Via
Business Wire
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
August 13, 2024
Via
Benzinga
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
August 05, 2024
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
August 01, 2024
Via
Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
August 05, 2024
Via
Benzinga
Exposures
COVID-19
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
August 05, 2024
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
July 15, 2024
Via
Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
July 15, 2024
Via
Chartmill
NASDAQ:GMAB, an undervalued stock with good fundamentals.
July 01, 2024
Via
Chartmill
10 Analysts Assess Genmab: What You Need To Know
June 20, 2024
Via
Benzinga
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024
From
Genmab A/S
Via
Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
Via
Benzinga
Exposures
Product Safety
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
June 26, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
Via
InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
June 21, 2024
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.